4 results
Approved WMOCompleted
see protocol summary
Approved WMOCompleted
This study will evaluate the efficacy and safety of gantenerumab compared with placebo in patients with early (prodromal to mild) Alzheimer's disease (AD).
Not approvedWill not start
The primary objective of this secondary prevention study is to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of gantenerumab, an anti-amyloid antibody, in amyloid-positive, cognitively unimpaired participants at risk for or…
Approved WMOPending
Main objective: To evaluate the efficacy of BIIB122 225 mg compared with placebo.Secondary objective: To evaluate the efficacy, safety and tolerability of BIIB122 225 mg compared with placebo in participants with early-stage PDObjective optional (…